Recent Updates
Recently added Catalysts
STRO Positive Sentiment

Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation

Key Takeaway: The Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting will feature a presentation on next-generation immunostimulatory antibody-drug conjugates (iADCs). These iADCs aim to combine tumor cell killing with immune activation, potentially leading to durable antitumor immunity. The presentation can be accessed through a provided link.
Price reaction · baseline $8.9 (2025-11-18 close) · hit pre-market · clean, no other STRO news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation highlights innovative immunostimulatory antibody-drug conjugates.
  • Focus on combining tumor cell killing with immune activation.
  • Promising potential for inducing durable antitumor immunity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
STRO-004
Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCC

Full Press Release Details

[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” categories=”off” comments=”off” admin_label=”15th Annual World ADC Conference – Presentation” _builder_version=”4.23.4″ title_level=”h2″ title_text_color=”#0c71c3″ title_font_size=”28px” title_letter_spacing=”1px” title_line_height=”1.4em” meta_text_color=”#000000″ global_colors_info=”{}”][/et_pb_post_title][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
Next-Generation Immunostimulatory Antibody-Drug Conjugates ( iADCs ) Combine Tumor Cell Killing with Immune Activation to Induce Durable Antitumor Immunity
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2025/11/SITC-2025-iADC.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_gallery gallery_ids=”17707″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_gallery][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][/et_pb_section]

Frequently Asked Questions

What are immunostimulatory antibody-drug conjugates?

Immunostimulatory antibody-drug conjugates (iADCs) are designed to combine tumor cell killing with immune system activation.

Where can I find the presentation from SITC 2025?

The presentation can be accessed through the provided link in the article.

What is the goal of the iADCs presented at SITC 2025?

The goal is to induce durable antitumor immunity by effectively targeting tumor cells.

Last updated: Nov 19, 2025